Nilotinib - A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond

Medicine & Life Sciences

• bcr-abl Fusion Proteins 92%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 82%
• Imatinib Mesylate 64%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60%
• Phosphotransferases 14%
• Myeloproliferative Disorders 12%
• Phase II Clinical Trials 11%
• Gastrointestinal Stromal Tumors 11%
• Cytogenetics 9%
• Therapeutics 9%
• Precursor Cell Lymphoblastic Leukemia-Lymphoma 9%
• Standard of Care 9%
• Leukemia 7%
• Clinical Trials 6%
• Mutation 5%

Chemical Compounds

• Nilotinib 100%
• Imatinib 85%
• Tyrosine Kinase Inhibitor 79%
• Resistance 17%
• Tyrosine 17%
• Cytogenetics 13%
• Phosphotransferase Inhibitor 12%
• Disorder 8%
• Mutation 8%